Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
The timeline for prior authorization Standard prior authorization requests through Anthem typically receive a response within 5 to 15 business days
More serious risks include: Pancreatitis Gallbladder issues Risk of thyroid tumors (observed in rodent studies) Patients must weigh these risks carefully, especially when using the medication off-label
In contrast, Wegovy is dosed at higher levels specifically optimized for weight loss
consider urinalysis
Signalling via its receptors located in various organs, including brain, GI tract and pancreas [9,10,11], GLP-1 provides a number of effects in the setting of T2D [11]